A new chemotherapy drug called Ixempra has received U.S. Food and Drug Administration approval to treat women with advanced breast cancer who haven't responded to three other types of chemotherapy.
Ixempra, which belongs to a new class of drugs called epothilones, is designed to stop the growth of cancer cells. It does this by targeting a protein called tubulin that helps cells proliferate, the Wall Street Journal reported. Bristol-Myers also is studying the use of Ixempra to treat earlier-stage breast cancer, as well as ovarian, prostate, renal, pancreatic and non small cell lung cancers.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment